

CBNPC (stades locorégionaux) : immunothérapie 1<sup>ère</sup> ligne

Références	Promoteur	Design	Sélection	Bras	N pts	R0	SSP (médiane)	Survie			p
								médiane	2 ans	5 ans	
<b>AC anti-PDL1</b>											
2017 Antonia (1–5) (6)	AstraZeneca	phIII R (double aveugle) « PACIFIC »	CBNPC st III non résécable sans progression après RT-CT	Durvalumab 10 mg/kg	473	NA	17,2 m	NA	66,3%	42,9 %	S
				Placebo	236		5,6 m	29,1 m	55,6%	33,4 %	

Références

1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. *New England Journal of Medicine*. 16 nov 2017;377(20):1919-29.
2. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *New England Journal of Medicine*. 13 déc 2018;379(24):2342-50.
3. Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. *The Lancet Oncology* [Internet]. déc 2019 [cité 23 déc 2020];20(12):1670-80. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S1470204519305194>
4. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. *Journal of Thoracic Oncology* [Internet]. févr 2020 [cité 23 déc 2020];15(2):288-93. Disponible sur: <https://linkinghub.elsevier.com/retrieve/pii/S1556086419335294>
5. Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. *J Thorac Oncol*. mai 2021;16(5):860-7.

6. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *J Clin Oncol*. 20 avr 2022;40(12):1301-11.